| NIDA Home > About NIDA > Organization > DPMCDA > Division Locator | |
Division of Pharmacotherapies and Medical Consequences of Drug Abuse (DPMCDA) |
|
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Name | Title/General Duties | Phone | |
| Office of the Director |
|||
| Phil Skolnick, Ph.D., D.Sc. | Director | 301-443-6173 | phil.skolnick@nih.gov |
| Ivan Montoya, M.D., M.P.H. | Deputy Director | 301 443 8639 | imontoya@nih.gov |
| David McCann, Ph.D. | Associate Director | 301 443 6173 | dmccann@nih.gov |
| Aida Klun, M.B.A., PMP | Program Analyst | 301 443 1122 | ak102w@nih.gov |
| Donna Inman | Program Analyst | 301 443 1078 | di13u@nih.gov |
| Medical Consequences Branch |
|||
| Jag Khalsa, Ph.D. | Chief | 301 443 2159 | jk98p@nih.gov |
| Jean Craft Comolli, R.N., M.B.A. | Grants: Oro Maxillary Complications | 301 402 0630 | jc282a@nih.gov |
| Guifang Lao, M.D., Ph.D. | Grants: Biomarkers, Non-Invasive Tools/Methods | 301-443-1061 | laog@mail.nih.gov |
| Barbara Herman, Ph.D | CIT Program and Scientific Research | 301 443 9799 | bh78q@nih.gov |
| Clinical/Medical Branch |
|||
| Ivan Montoya, M.D., M.P.H. | Chief (acting) | 301 443 8639 | imontoya@nih.gov |
| Shwe Gyaw, M.D. | Medical Safety Officer | 301 443 2281 | shwe.gyaw@nih.gov |
| Ann Anderson, MD. | Medical Safety Officer | 301 435 0767 | aa135m@nih.gov |
| Shou Hua Li, Ph.D. | Statistician | 301 443 9811 | sli1@nida.nih.gov |
| Liza Gorgon, M.A. | Clinical Trials - Phase 2 and 3 and nicotine | 301 443 1138 | lgorgon@nih.gov |
| Jurij Mojsiak, M.S. | Clinical Pharmacologist - Phase 1 | 301 443 9804 | jm200p@nih.gov |
| Regulatory Affairs Branch |
|||
| Robert "Bob" Walsh, B.S., R.A.C. | Chief | 301 443 9825 | rwalsh@nih.gov |
| Marta De Santis, Ph.D. | Regulatory Affairs Specialist | 301 443 0886 | mdesantis@ nida.nih.gov |
| Chemistry and Pharmaceutics Branch |
|||
| Nora Chiang, Ph.D. | Chief | 301 443 8099 | nchiang@nih.gov |
| Richard "Rik" Kline, Ph.D. | Medicinal Chemist | 301 443 8293 | rik@nih.gov |
| Moo Park, Ph.D. | Chemist Biopharmaceutics, Pharmaceutics, and Pharmacokinetics | 301 443 9813 | mp264a@nih.gov |
| Ming Shih, Ph.D. | Chemist - Medicinal/Analytical | 301 443 8422 | mshih@mail.nih.gov |
| Amrat Patel, Ph.D. | Pharmacologist - Drug Metabolism and Pharmacokinetics | 301 443 8476 | ap79g@nih.gov |
| Charles Marschke, B.S. | Chemist: Management Discovery Compound Rresources | 301 443 8211 | cm109u@nih.gov |
| Medications Discovery and Toxicology Branch |
|||
| Jane B. Acri, Ph.D. | Chief | 301 443 8489 | ja96v@nih.gov |
| Naresh Chand, D.V.M., Ph.D. | Cardiotoxicologist | 301 443 8895 | nc114a@nih.gov |
| Nathan M. Appel, Ph.D. | Neurotoxicologist | 301 443 8475 | nappel@nih.gov |
| Hirsch Davis, M.A. | Psychologist | 301 443 8849 | hdavis@nida.nih.gov |
| Carol Hubner, Ph.D. | Pharmacologist | 301 443 4459 | ch83a@nih.gov |
| David White, Ph.D. | Pharmacologist | 301 443 8889 | whitedav@nida.nih.gov |
| Medications Research Grants Branch |
|||
| Jamie Biswas, Ph.D. | Chief, Immunotherapy; Adolescent Drug Abuse; Substance Abuse Treatment in the Criminal Justice System: Cocaine, Opiates, Cannabis | 301 443 8096 | jb168r@nih.gov |
| Aidan Hampson, Ph.D. | Pharmacology, Drug Development, Clinical Trial Cannabis, Methamphetamine, Opiates | 301 443 8039 | Aidan.Hampson@nih.gov |
| Kristopher Bough, Ph.D. | Neuroscientist, Phase I Clinical Trials, SBIR/STTRs, Translational Research, Cocaine, Nicotine | 301 443 9800 | boughk@mail.nih.gov |
DPMCDA IndexAbout NIDA Contents |
PDF documents require the free Adobe ReaderExternal link, please review our disclaimer here.. Microsoft Word documents require the free Microsoft Word viewerExternal link, please review our disclaimer here..
Microsoft PowerPoint documents require the free Microsoft PowerPoint viewerExternal link, please review our disclaimer here.. Flash content requires the free Adobe Flash PlayerExternal link, please review our disclaimer here..
NIH...Turning Discovery Into Health
External link, please review our disclaimer here.
External link, please review our disclaimer here.
External link, please review our disclaimer here.


